TapImmune Inc. (OTCQB: TPIV) is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease, and the Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems, according to the company’s website (see here: www.TapImmune.com). SNNLive caught up with Glynn Wilson, Ph.D., Chairman & CEO of TapImmune, Inc., at the Source Capital 2016 Disruptive Growth & Healthcare Conference in New York City, NY.
In this video interview, Dr. Wilson and our host discuss the following topics:
- Overview of TapImmune, Inc.
- Where the science was developed
- Target indications
- Clinical development
- When the company’s vaccines should be taken
- Update since our last interview (click here)
- Orphan drug designation
- Difference between TapImmune vaccines vs. standard of care
- Milestones and goals for 2016
For more information about TapImmune, Inc., go to: www.TapImmune.com
The interview may contain forward looking statements about TapImmune, Inc. See TapImmune's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions